Further studies demonstrated that H19 modulates HE4 expression via miR-140, suggesting a novel H19/miR-140/HE4 regulatory pathway for α-mangostin’s potential therapeutic impact in diabetes mellitus [162]. Here, WFDC2 is linked to diabetes mellitus.